Literature DB >> 14758538

A study of the distributional characteristics of FMR1 transcript levels in 238 individuals.

Emily G Allen1, Weiya He, Maneesha Yadav-Shah, Stephanie L Sherman.   

Abstract

Fragile X syndrome, the most common form of inherited mental retardation, is caused by hyperexpansion and hypermethylation of a CGG repeat tract in the 5' untranslated region of the FMR1 gene. This methylation causes the gene to be transcriptionally silenced. In addition to the common allele form with less than 41 repeats, there are two other allelic forms of the FMR1 gene that are unmethylated: premutation (61-200 CGG repeats) and intermediate (41-60 CGG repeats). Recently, premutation-specific phenotypes not related to fragile X syndrome have been reported: a 20-fold increased risk for premature ovarian failure (POF) among female carriers and an increased risk for a tremor ataxia syndrome (TAS) primarily among older male carriers. At the molecular level, increased levels of FMR1 transcript have been observed among premutation carriers. Increased levels of transcript may be causally related to the POF or TAS phenotypes or may be a surrogate of some other allelic property. In this report, we have examined the distributional properties of transcript levels by repeat size and gender among 238 individuals. We have confirmed a significant linear relationship between transcript level and repeat size in males and females. The evidence for the linear effect is primarily within the premutation size alleles.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14758538     DOI: 10.1007/s00439-004-1086-x

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  19 in total

1.  Methylation of ZNF261 as an assay for determining X chromosome inactivation patterns.

Authors:  Christy Beever; Betty P Y Lai; Sarah E L Baldry; Maria S Peñaherrera; Ruby Jiang; Wendy P Robinson; Carolyn J Brown
Journal:  Am J Med Genet A       Date:  2003-07-30       Impact factor: 2.802

2.  Characterization and expression of a cDNA encoding the human androgen receptor.

Authors:  W D Tilley; M Marcelli; J D Wilson; M J McPhaul
Journal:  Proc Natl Acad Sci U S A       Date:  1989-01       Impact factor: 11.205

Review 3.  Triplet repeats, RNA secondary structure and toxic gain-of-function models for pathogenesis.

Authors:  R Galvão; L Mendes-Soares; J Câmara; I Jaco; M Carmo-Fonseca
Journal:  Brain Res Bull       Date:  2001 Oct-Nov 1       Impact factor: 4.077

4.  Clinical involvement and protein expression in individuals with the FMR1 premutation.

Authors:  F Tassone; R J Hagerman; A K Taylor; J B Mills; S W Harris; L W Gane; P J Hagerman
Journal:  Am J Med Genet       Date:  2000-03-13

5.  Translational suppression by trinucleotide repeat expansion at FMR1.

Authors:  Y Feng; F Zhang; L K Lokey; J L Chastain; L Lakkis; D Eberhart; S T Warren
Journal:  Science       Date:  1995-05-05       Impact factor: 47.728

6.  The FMR1 CGG repeat mouse displays ubiquitin-positive intranuclear neuronal inclusions; implications for the cerebellar tremor/ataxia syndrome.

Authors:  Rob Willemsen; Marianne Hoogeveen-Westerveld; Surya Reis; Joan Holstege; Lies-Anne W F M Severijnen; Ingeborg M Nieuwenhuizen; Mariette Schrier; Leontine van Unen; Flora Tassone; Andre T Hoogeveen; Paul J Hagerman; Edwin J Mientjes; Ben A Oostra
Journal:  Hum Mol Genet       Date:  2003-05-01       Impact factor: 6.150

7.  FMR1 protein: conserved RNP family domains and selective RNA binding.

Authors:  C T Ashley; K D Wilkinson; D Reines; S T Warren
Journal:  Science       Date:  1993-10-22       Impact factor: 47.728

8.  Variation of the CGG repeat at the fragile X site results in genetic instability: resolution of the Sherman paradox.

Authors:  Y H Fu; D P Kuhl; A Pizzuti; M Pieretti; J S Sutcliffe; S Richards; A J Verkerk; J J Holden; R G Fenwick; S T Warren
Journal:  Cell       Date:  1991-12-20       Impact factor: 41.582

Review 9.  The fragile X premutation: into the phenotypic fold.

Authors:  Randi J Hagerman; Paul J Hagerman
Journal:  Curr Opin Genet Dev       Date:  2002-06       Impact factor: 5.578

Review 10.  FMR1 and the fragile X syndrome: human genome epidemiology review.

Authors:  D C Crawford; J M Acuña; S L Sherman
Journal:  Genet Med       Date:  2001 Sep-Oct       Impact factor: 8.822

View more
  63 in total

1.  Ovarian histopathological and ubiquitin-immunophenotypic features in fragile X-associated primary ovarian insufficiency: a study of five cases and selected controls.

Authors:  Martin C Chang; John J DeCaro; Mei Zheng; Marla Gearing; Lisa Shubeck; Stephanie L Sherman; Corrine K Welt
Journal:  Histopathology       Date:  2011-10-18       Impact factor: 5.087

Review 2.  Advances in understanding the molecular basis of FXTAS.

Authors:  Dolores Garcia-Arocena; Paul J Hagerman
Journal:  Hum Mol Genet       Date:  2010-04-29       Impact factor: 6.150

3.  FMR1 repeat sizes in the gray zone and high end of the normal range are associated with premature ovarian failure.

Authors:  Karla L Bretherick; Margo R Fluker; Wendy P Robinson
Journal:  Hum Genet       Date:  2005-06-02       Impact factor: 4.132

4.  Polymerase chain reaction, nuclease digestion, and mass spectrometry based assay for the trinucleotide repeat status of the fragile X mental retardation 1 gene.

Authors:  Eric D Dodds; Flora Tassone; Paul J Hagerman; Carlito B Lebrilla
Journal:  Anal Chem       Date:  2009-07-01       Impact factor: 6.986

5.  CNS expression of murine fragile X protein (FMRP) as a function of CGG-repeat size.

Authors:  Anna Lisa Ludwig; Glenda M Espinal; Dalyir I Pretto; Amanda L Jamal; Gloria Arque; Flora Tassone; Robert F Berman; Paul J Hagerman
Journal:  Hum Mol Genet       Date:  2014-01-23       Impact factor: 6.150

6.  Expanded clinical phenotype of women with the FMR1 premutation.

Authors:  Sarah M Coffey; Kylee Cook; Nicole Tartaglia; Flora Tassone; Danh V Nguyen; Ruiqin Pan; Hannah E Bronsky; Jennifer Yuhas; Mariya Borodyanskaya; Jim Grigsby; Melanie Doerflinger; Paul J Hagerman; Randi J Hagerman
Journal:  Am J Med Genet A       Date:  2008-04-15       Impact factor: 2.802

7.  Aging in fragile X syndrome.

Authors:  Agustini Utari; Evan Adams; Elizabeth Berry-Kravis; Alyssa Chavez; Felicia Scaggs; Lily Ngotran; Antoniya Boyd; David Hessl; Louise W Gane; Flora Tassone; Nicole Tartaglia; Maureen A Leehey; Randi J Hagerman
Journal:  J Neurodev Disord       Date:  2010-05-12       Impact factor: 4.025

8.  Fragile X and autism: Intertwined at the molecular level leading to targeted treatments.

Authors:  Randi Hagerman; Gry Hoem; Paul Hagerman
Journal:  Mol Autism       Date:  2010-09-21       Impact factor: 7.509

9.  Translation of the FMR1 mRNA is not influenced by AGG interruptions.

Authors:  Anna L Ludwig; Christopher Raske; Flora Tassone; Dolores Garcia-Arocena; John W Hershey; Paul J Hagerman
Journal:  Nucleic Acids Res       Date:  2009-09-14       Impact factor: 16.971

10.  Improved methodology for assessment of mRNA levels in blood of patients with FMR1 related disorders.

Authors:  David E Godler; Danuta Z Loesch; Richard Huggins; Lavinia Gordon; Howard R Slater; Freya Gehling; Trent Burgess; K H Andy Choo
Journal:  BMC Clin Pathol       Date:  2009-06-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.